From Justin · PEDs & Compounds
Tirzepatide monograph
Justin Harris — IFBB Pro Coach
From Justin
Tirzepatide is solid for fat loss -- it's a dual GIP/GLP-1 receptor agonist that's FDA-approved for diabetes and weight management, so it has real clinical backing unlike some of the research chemicals floating around. The mechanism is appetite suppression and slower gastric emptying. It doesn't directly burn fat or build muscle -- it just makes it much easier to stick to a caloric deficit because you're not constantly hungry. The weight loss in clinical trials is often skewed towards lean tissue, but a proper bodybuilding diet will avoid that risk. For bodybuilding use, I'm cautious about it. The long-term effects on the motivation systems of the body aren't precisely understood, and the same pathway that helps fight addiction may have negative effects on other reward-driven activities, like bodybuilding. Start conservative if you're going to use it -- typical dosing ramps from 2.5mg weekly up to 15mg max, but most people see effects around 5-7.5mg. The side effects are mostly GI -- nausea, diarrhea, constipation. Most people adapt after a few weeks.
Tirzepatide
Overview
Tirzepatide is an FDA-approved once-weekly injectable peptide drug that activates both the GIP and GLP-1 receptors. Clinically, it is used for type 2 diabetes and chronic weight management, with strong effects on A1c, appetite, and body weight. For bodybuilding/performance use, the real effect is appetite suppression and fat loss, not direct anabolic performance enhancement.
Pharmacokinetics & Mechanism
- Class: Dual incretin receptor agonist; GIP/GLP-1 receptor agonist peptide drug
- Mechanism of action: Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. It enhances glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and lowers food intake/body weight. The fatty diacid side chain promotes albumin binding and prolongs exposure, enabling once-weekly dosing.
- Target(s): Primary targets: GIP receptor and GLP-1 receptor. Downstream effects include glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite/energy intake. No androgenic, anabolic, or beta-adrenergic performance target is established.
- Route(s) of administration: Subcutaneous injection only. Label products are supplied as single-dose pens/vials and, for some presentations, multi-dose vial/single-patient-use pen formats.
- Onset: Glycemic and appetite effects begin after injection, but the gastric-emptying delay is largest after the first dose and then diminishes over time. Peak plasma concentrations occur about 8 to 72 hours after subcutaneous dosing. Clinically meaningful weight-loss effects typically develop over weeks, not days.
- Half-life: Approximately 5 days in humans, supporting once-weekly dosing. This is consistent across the FDA label and is not a DAC/extended-release peptide variant; the long duration comes from albumin binding and the molecule’s design.
- Metabolism / clearance: Metabolized mainly by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis. Clearance is low (about 0.061 L/h), bioavailability is about 80% after subcutaneous administration, plasma protein binding is about 99%, and intact drug is not observed in urine or feces. Excretion is via urine and feces as metabolites.
Members from here
The opener is free so Google can find us. The rest is how Justin actually uses it. That is the $29.99.
6 more minutes of this lecture, the full Troponin University library, and the TroponinIQ coach built on the same reasoning — one membership.
Keep reading
Source attribution
- [1]Troponin Nutrition knowledge base — Tirzepatide